Key points are not available for this paper at this time.
Abstract Nanoparticle radioenhancement offers a promising strategy for augmenting radiotherapy by locally increasing radiation damage to tumor tissue. While past research has predominantly focused on nanomaterials with high atomic numbers, such as Au and HfO 2 , recent work has revealed that their radioenhancement efficacy decreases considerably when using clinically relevant megavoltage X‐rays as opposed to the orthovoltage X‐rays typically employed in research settings. Here, radiocatalytically active Ti‐based nanomaterials for clinical X‐ray therapy settings are designed. A range of candidate materials, including TiO 2 (optionally decorated with Ag or Pt nanoseeds), Ti‐containing metal–organic frameworks (MOFs), and 2D Ti‐based carbides known as Ti 3 C 2 T x MXenes, is investigated. It is demonstrated that these titanium‐based candidates remain consistently performant across a wide energy spectrum, from orthovoltage to megavoltage. This sustained performance is attributed to the catalytic generation of reactive oxygen species, moving beyond the simple physical dose enhancements associated with photoelectric effects. Beyond titania, emergent materials like titanium‐based MOFs and MXenes exhibit encouraging results, achieving dose‐enhancement factors of up to three in human soft tissue sarcoma cells. Notably, these enhancements are absent in healthy human fibroblast cells under similar conditions of particle uptake, underscoring the selective impact of titanium‐based materials in augmenting radiotherapy across the clinically relevant spectral range.
Gerken et al. (Tue,) studied this question.